This roundtable series assesses later-line treatment of patientswith relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.
BCMA Therapies Changing Treatment in Relapsed/Refractory Multiple Myeloma
March 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses how targeting patients with relapsed/refractory multiple myeloma with B-cell maturation antigens like teclistamab is changing the treatment landscape.
MajesTEC-1 Results Show Efficacy for Teclistamab in Multiple Myeloma
May 9th 2023In a live virtual event, Jens Hillengass discussed the results of the MajesTEC-1 study and how teclistamab is used to treat patients with relapsed/refractory multiple myeloma. This is the second article in a 2-article series on this case.
Key Factors Influence Therapeutic Choices in Penta-Refractory Myeloma
June 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, discussed the choice of therapy for a patient with relapsed/refractory multiple myeloma. This is is the first of 2 articles based on this event.
Physicians Share Perceptions of BCMA-Targeted Therapies for Multiple Myeloma
July 11th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, and other physicians discussed how they expect to use bispecific agents and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma as the field advances.
Long-Term Depth of Response With Teclistamab Continues in RRMM
August 28th 2023In the first article of a 2-part series, Ajay Nooka, MD, MPH, discussed both the initial and follow-up results of the MajesTEC-1 trial that showed the potency of teclistamab in patients with relapsed/refractory multiple myeloma.
Teclistamab Toxicities Highly Manageable in R/R Multiple Myeloma
September 19th 2023In the second article of a 2-part series, Ajay Nooka, MD, MPH, discussed the exciting safety profile of teclistamab and how to manage major adverse events, like cytokine release syndrome, for patients with relapsed/refractory multiple myeloma.
Targeting BCMA With Teclistamab Produces Impactful Results in RRMM
October 12th 2023In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.
Manageable Toxicities Allow For Flexible Treatment in RRMM
November 2nd 2023In the second article of this 2-part series, Sikander Ailawadhi, MD, discusses how understanding the safety profile of the bispecific antibody teclistamab allows for physicians to treat and monitor their patients in a better way for them.
Teclistamab Shows Strong Efficacy in Triple-Refractory Multiple Myeloma
December 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
Elranatamab Shows Efficacy of BCMA-Targeted Therapy in Multiple Myeloma
January 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MagnetisMM-1 and MagnetisMM-3 trials of elranatamab in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.